Adult Myopia Market Insight, Epidemiology And Market Forecast -2030

August 21 00:40 2021
Adult Myopia Market Insight, Epidemiology And Market Forecast -2030
DelveInsight Business Research LLP
DelveInsight’s ‘Adult Myopia Market’ report delivers an in-depth understanding of historical and forecasted epidemiology as well as the market trends of Adult Myopia in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Adult Myopia Market

The market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted market size of Adult Myopia symptoms from 2018 to 2030 segmented by seven major markets. The report also covers current Adult Myopia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Adult Myopia Market Outlook

The Adult Myopia market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Adult Myopia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Adult Myopia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Adult Myopia market in 7MM is expected to change in the study period 2018–2030.

Key Findings

This section includes a glimpse of the Adult Myopia market in 7MM. In 2020, the market size of Adult Myopia in the 7MM was USD 228.89 million, which is expected to rise at a significant CAGR of 10.46% throughout the forecast period (2018–2030).

Scope of the Report

  • The report covers the descriptive overview of Adult Myopia, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Adult Myopia epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Adult Myopia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Adult Myopia market; historical and forecasted, is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Adult Myopia market

Table of contents

1. Key Insights

2. Report Introduction

3. Adult Myopia Market Overview at a Glance

3.1. Market Share (%) Distribution of Adult Myopia in 2018

3.2. Market Share (%) Distribution of Adult Myopia in 2030

4. Executive Summary of Adult Myopia

5. Adult Myopia Market: Future perspective

6. Disease Background and Overview

6.1. Introduction

6.2. Terminology and Classification

6.2.1. Myopia, High Myopia, and Pathologic Myopia

6.2.2. Myopic Macular Degeneration (MMD)

6.3. Causes

6.4. Risk Factors

6.4.1. Environmental Risk Factors

6.4.2. Genetic Risk Factors

6.5. Pathogenesis

6.5.1. Ocular Biometric Changes in Human Myopia

6.5.2. Visual Environment, Emmetropization, and Myopia

6.5.3. Monochromatic Higher-Order Aberrations as a Myopigenic Stimulus

6.5.4. Accommodation

6.6. Diagnosis

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. 7MM Total Prevalent Patient Population of Adult Myopia

7.3. Assumptions and Rationale

7.4. The United States

7.4.1. Prevalence of Adult Myopia in the United States

7.4.2. Prevalence of Myopic Choroidal neovascularisation in the United States

7.5. EU5

7.5.1. Germany

7.5.1.1. Prevalence of Adult Myopia in Germany

7.5.1.2. Prevalence of Myopic Choroidal neovascularisation in Germany

7.5.2. France

7.5.2.1. Prevalence of Adult Myopia in France

7.5.2.2. Prevalence of Myopic Choroidal neovascularisation in France

7.5.3. Italy

7.5.3.1. Prevalence of Adult Myopia in Italy

7.5.3.2. Prevalence of Myopic Choroidal neovascularisation in Italy

7.5.4. Spain

7.5.4.1. Prevalence of Adult Myopia in Spain

7.5.4.2. Prevalence of Myopic Choroidal neovascularisation in Spain

7.5.5. United Kingdom

7.5.5.1. Prevalence of Adult Myopia in United Kingdom

7.5.5.2. Prevalence of Myopic Choroidal neovascularisation in the UK

7.6. Japan

7.6.1. Prevalence of Adult Myopia in Japan

7.6.2. Prevalence of Myopic Choroidal Neovascularisation in Japan

8. Control of Myopia

8.1. Optical Control

8.1.1. Spectacle methods

8.1.2. Contact lens methods

8.1.3. Time Spent Outdoors and Behavioral Influences

8.1.4. Pharmacologic and Therapeutic Control

8.1.4.1. Atropine

8.1.4.2. 7–Methylxanthine

8.2. Surgical Interventions for Controlling Myopia Progression

8.3. Specific Conclusions and Recommendations by World Health Organization (WHO)

9. Organizations contributing towards Adult Myopia

10. Patient Journey

11. Case Reports

11.1. Key Findings

11.2. Market Size of Adult Myopia (18-25) in 7MM

11.3. Market Size of Myopic choroidal neovascularization in 7MM

11.4. Market Outlook

11.5. United States Market Size

11.5.1. Market Size of Adult Myopia (18-25) in United States

11.5.2. Market size of Myopic Choroidal neovascularization in the US

11.6. EU-5 Market Size

11.6.1. Germany

11.6.1.1. Market size of Adult Myopia (18-25) in Germany

11.6.1.2. Market size of Myopic Choroidal neovascularization in Germany

11.6.2. France

11.6.2.1. Market size of Adult Myopia (18-25) in France

11.6.2.2. Market size of Myopic Choroidal neovascularization in France

11.6.3. Italy

11.6.3.1. Market size of Adult Myopia (18-25) in Italy

11.6.3.2. Market size of Myopic Choroidal neovascularization in Italy

11.6.4. Spain

11.6.4.1. Market size of Adult Myopia (18-25) in Spain

11.6.4.2. Market size of Myopic Choroidal neovascularization in Spain

11.6.5. United Kingdom

11.6.5.1. Market size of Adult Myopia (18-25) in the United Kindgom

11.6.5.2. Market size of Myopic Choroidal neovascularization in the United Kingdom

11.7. Japan

11.7.1. Market size of Adult Myopia (18-25) in Japan

11.7.2. Market size of Myopic Choroidal neovascularization in Japan

12. KOL Views

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. Unmet Needs

17. Appendix

17.1. Bibliography

17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

 

Request for sample pages @ Adult Myopia market size

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/atlantanewsonlin/public_html/news.bostonnewsdesk.com/wp-content/themes/gadgetine-theme/includes/single/post-tags-categories.php on line 7
  Categories: